Elliot H. Choi, MD PhD

Ophthalmology Resident at UCLA @UCLASteinEye 👁 | MD/PhD at Case Western @CWRUSOM 🩺 | BA/MS at Johns Hopkins @JohnsHopkins 🧠 | 최형국, 안과 전공의

[Elliot H. Choi, MD PhD @ElliotHChoi]

Last year, we did not match.

This year, my wife matched in dermatology at UC Irvine, and I matched in ophthalmology at UCLA. During the reapplication process, we received the greatest gift from God, our son, who has brought us immense joy. Thank you everyone! #Match2024

[David R. Liu @davidrliu]

Today in @NatureNano, we report an all-RNA lipid nanoparticle (LNP) system for efficient in vivo prime editing (PE). We identify bottlenecks in transient prime editor delivery, develop a workflow for LNP optimization, and use it to rescue a mouse model of phenylketonuria.
https://t.co/WAH8LHAb9z
1/12

[David R. Liu @davidrliu]

Today in @NatBiotech, we report the directed evolution of structured RNA motifs that enhance the efficiency of prime editing. Iterated high-throughput pooled screens and mutagenesis of these small RNA elements improved transient pegRNA lifetime.
https://t.co/ZiytYXicaJ
1/11

[Elliot H. Choi, MD PhD @ElliotHChoi]

@davidrliu @NatBiotech Congratulations, Dr. Liu! Amazing work.

[David R. Liu @davidrliu]

Today in @natBME we report an in vivo base editing strategy that corrects a common disease-causing mutation and rescues pathology in a mouse model of Zellweger spectrum disorder (ZSD) and restore peroxisomal function in patient derived cells. This work highlights the promise of precision genome editing for treating peroxisomal biogenesis disorders.
1/13

[David R. Liu @davidrliu]

Below is the story of the first patient treated with a prime-edited therapeutic, developed by @PrimeMedicine in a trial led by Dr. Élie Haddad and his team at CHU Sainte-Justine. This teenager suffered from chronic granulomatous disease (CGD), an immunodeficiency, and now—10 months after treatment—the patient is healthy, stable, and living with a functioning immune system. Tracy Attebury, whose story was previously told by @ginakolata @nytimes, was the second patient treated with a prime-edited therapeutic.

https://t.co/ZiVq1SmYsn

[Elliot H. Choi, MD PhD @ElliotHChoi]

@davidrliu @washingtonpost Congratulations, Dr. Liu!

[Elliot H. Choi, MD PhD @ElliotHChoi]

@joonholee24 Love it

[David R. Liu @davidrliu]

Today in @Nature we report a new prime editing strategy that can rescue a common cause of many genetic diseases in a disease-agnostic manner. This approach converts a redundant endogenous tRNA into an optimized suppressor tRNA, enabling a single prime edit to rescue premature stop codons across different diseases.
(1/15)
https://t.co/zs0qu5bhXx

[UCLA Stein Eye Institute @UCLASteinEye]

We are beyond excited to welcome the UCLA #Ophthalmology Residency Class of 2029!

Congratulations to this incredible group of future eye surgeons—we can’t wait to have you join us!! #MatchDay

[David R. Liu @davidrliu]

Today we report in @NatureBiotech a system for the laboratory evolution of engineered virus-like particles (eVLPs) that enables the discovery of eVLP variants with desired properties, including improved production and delivery potency. 1/13
PDF: https://t.co/OKvvoawP9n

[Elliot H. Choi, MD PhD @ElliotHChoi]

@lauribto Thank you so much for your kind words!

[Elliot H. Choi, MD PhD @ElliotHChoi]

Today we share a review of genome editing in the treatment of ocular diseases. The review covers applications of genome editing to ocular diseases from the anterior to the posterior segment and the current limitations in clinical translation. https://t.co/nihcrKsrv8

[Elliot H. Choi, MD PhD @ElliotHChoi]

@FilizaKoya Please check the DM!

[Elliot H. Choi, MD PhD @ElliotHChoi]

Last year, we did not match.

This year, my wife matched in dermatology at UC Irvine, and I matched in ophthalmology at UCLA. During the reapplication process, we received the greatest gift from God, our son, who has brought us immense joy. Thank you everyone! #Match2024

[Elliot H. Choi, MD PhD @ElliotHChoi]

We've developed a systems pharmacology-based strategy targeting GPCRs and evaluated its efficacy in multiple inherited retinal degeneration models. Proud to contribute to the study and congratulations to Henri @Dr_HLeinonen! #ophthalmology #retina
https://t.co/PzJQkgxDeH

[David R. Liu @davidrliu]

Today we report in @natBME the eePASSIGE system, which uses evolved and engineered recombinases and prime editing to integrate large gene-sized DNA cargoes into the mammalian genome in an efficient, precise, and targeted manner. (1/13)
https://t.co/xvjTwgApde

[Ty Miller Lab @TyMillerLab]

I am incredibly excited to announce the opening of the @TyMillerLab at @CWRUSOM and @UHhospitals in Cleveland! My lab will be dedicated to creating effective immunotherapies for brain tumor patients. Learn more at our freshly minted website - https://t.co/sg8YjNyfNf

[The Postdoctoral @thepostdoctoral]

Swapping stethoscope for pipette to understand diabetic retinopathy - Emma Lessieur Contreras is a postdoctoral fellow at the University of California, Irvine under the supervision of Timothy Kern, focusing on the immune ... - https://t.co/vS38iIzSJO

[Elliot H. Choi, MD PhD @ElliotHChoi]

#ophthalmology #eye #retina #vision #biochemistry #electrophysiology

[Elliot H. Choi, MD PhD @ElliotHChoi]

Happy to share our study on the physiological role of CRALBP in the retinal pigment epithelium and Müller glia @CellReports. The functional role of these two cellular pools is debated. Congratulations to Marco Bassetto and Philip Kiser at @UciCtvr https://t.co/NEXd6CoOXx

[Elliot H. Choi, MD PhD @ElliotHChoi]

#Ophthalmology #CommunitySupport #pediatrics #children #publichealth #healthcare

[Elliot H. Choi, MD PhD @ElliotHChoi]

The UCI Eye Mobile offers free vision screenings and comprehensive eye exams to underserved children. Today we share a study on children who required referral to an ophthalmologist from the Eye Mobile and the impact of COVID-19. @UCIrvineHealth @UCIrvine https://t.co/bpfmNEEqLD